Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
On this page:OverviewPublicationsResearchersKey papersJournalsOpen accessInstitutions
ScholarIQanswers from OpenAlex

Psoriasis: Treatment and Pathogenesis

TopicLeading institutions, researchers & key papers

This cluster of papers focuses on the reciprocal developmental pathways for the generation of pathogenic effector TH17 cells and regulatory T cells, particularly in the context of autoimmune inflammation, interleukin-23, psoriasis, and the role of cytokines such as TGF-ß. It also explores the differentiation, cytokine profile, and function of human interleukin 17–producing helper T cells.

566
Works

How has Psoriasis: Treatment and Pathogenesis's publication output changed over time?

ScholarIQpublication output · 2006–2020

Output declined67% over the shown period — from 3 works in 2006 to 1 in 2020.

3
1
4
1
1
1
1
1
1
1
2006200720082009201020122016201720192020

What are the most-cited papers on Psoriasis: Treatment and Pathogenesis?

ScholarIQmost cited works
Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens
Yan Zheng, Patricia Valdez, Dimitry M. Danilenko, Yan Hu, M. Logan Susan, Qian Gong, Alexander R. Abbas, Zora Modrušan, Nico Ghilardi, Frédéric J. de Sauvage, Wenjun Ouyang
Nature Medicine. 20081,918 Citations
Risk of Myocardial Infarction in Patients With Psoriasis
Joel M. Gelfand, Andrea L. Neimann, Daniel B. Shin, Xingmei Wang, David J. Margolis, Andrea B. Troxel
JAMA. 20061,899 Citations
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
Craig L. Leonardi, Alexa B. Kimball, Kim Papp, Newman Yeilding, Cynthia Guzzo, Yuhua Wang, Shu Li, Lisa T. Dooley, Kenneth B. Gordon
The Lancet. 20081,873 Citations
Phenotypic and functional features of human Th17 cells
Francesco Annunziato, Lorenzo Cosmi, Veronica Santarlasci, Laura Maggi, Francesco Liotta, Benedetta Mazzinghi, Eliana Parente, Lucia Filì, Simona Ferri, Francesca Frosali, Francesco Giudici, Paola Romagnani, Paola Parronchi, Francesco Tonelli, Enrico Maggi, Sergio Romagnani
S22947807. 20071,858 CitationsOPEN ACCESS
Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis
Yan Zheng, Dimitry M. Danilenko, Patricia Valdez, Ian Kasman, Jeffrey Eastham‐Anderson, Jianfeng Wu, Wenjun Ouyang
Nature. 20061,854 Citations

Where is Psoriasis: Treatment and Pathogenesis research published, and who funds it?

ScholarIQvenues & funding sources

TOP JOURNALS

S1379053093,527
S587275093,111
JAMA1,899

TOP FUNDERS

National Science Foundation
NIH
Wellcome Trust
European Research Council
Funder breakdown is a member featureSign up free to unlock

How much of the research on Psoriasis: Treatment and Pathogenesis is open access?

ScholarIQopen access share
40%OPEN ACCESS
Gold
0%
Green
13%
Hybrid
7%
Bronze
20%
Closed
60%

Related on ScholarIQ

Classification criteria for psoriatic arthritis: Development of new criteria from a large international study
Paper
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Paper
Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens
Paper
Risk of Myocardial Infarction in Patients With Psoriasis
Paper
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
Paper
Phenotypic and functional features of human Th17 cells
Paper
470M+ articles · free account